+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating the effectiveness of intravenous brincidofovir IV BCV compared to intravenous cidofovir IV CDV in adults and children who have undergone allogeneic hematopoietic cell transplantation allo-HCT and have adenovirus viremia. This Phase 3, multi-center, randomized, open-label study aims to determine which treatment better clears adenovirus in this high-risk population, following guidelines that recommend weekly monitoring of adenovirus levels. Participants will be randomly assigned to receive either IV BCV or IV CDV. Treatment will continue until adenovirus DNA is undetectable in plasma for two consecutive tests one week apart or for a maximum of 12 weeks, whichever happens first. Subjects who achieve virus clearance but later experience recurrence may be retreated with their originally assigned drug, but no crossover between drugs is allowed. Safety data will be reviewed regularly by an independent monitoring board, and an adjudication committee will evaluate clinical responses. Participants will be assessed weekly through the treatment period and followed for a total of 24 weeks after randomization. Key evaluations include virologic response at Week 5 Day 1 and continued monitoring at test of cure four weeks after last dose, and at Weeks 12 and 24. Blood samples for drug concentrations will be collected, and all visits and assessments must be completed regardless of treatment duration to monitor efficacy and safety throughout the study.

Age: 2Months +All GendersPhase 3
81 locations
M

Actively Recruiting

Researchers are collecting real-world data on the safety and performance of AtriCure devices used to treat Inappropriate Sinus Tachycardia IST and Postural Tachycardia Syndrome POTS. This observational registry includes both retrospective and prospective data from multiple centers in the US and internationally, aiming to better understand outcomes following these treatments. The study involves patients who have either undergone or are scheduled to have epicardial and endocardial hybrid ablation procedures using commercially available AtriCure devices to target cardiac tissue for IST or POTS. There are no experimental drugs or placebos the study focuses on monitoring the real-world use of these devices. Participants medical records and outcomes will be observed over a period of five years to capture long-term data on device use and treatment results. Researchers will collect information regarding the procedures, patient safety, and device performance without altering standard medical care. Participation includes providing informed consent and allowing access to relevant health information for study purposes.

Age: 18Years - 100YearsAll Genders
15 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness, safety, and lasting effects of faricimab in Caucasian patients with symptomatic macular polypoidal choroidal vasculopathy PCV. PCV is a type of choroidal vasculopathy that causes hemorrhagic and exudative macular degeneration. This study aims to see how intravitreal injections of faricimab 6 mg affect best corrected visual acuity BCVA outcomes in these patients, addressing the current unmet needs due to disease heterogeneity and treatment challenges. The study involves administering faricimab injections directly into the eye following a treat and extend regimen tailored to each patient. It is an open-label, single-arm study lasting approximately 100 weeks, including a screening period of up to 28 days, a 12-week treatment initiation period, and a subsequent treat and extend phase extending to week 100. Participants receive faricimab at intervals up to 24 weeks based on their response and the study protocol. Participants will undergo regular eye examinations, safety assessments, and visual acuity testing using the ETDRS protocol. The study will monitor changes in BCVA from baseline through weeks 40, 44, 48, and up to 104 weeks, along with imaging to assess polypoidal lesion regression and retinal thickness. Adverse events will be tracked throughout the study. Overall participation spans more than two years, allowing detailed evaluation of faricimabs effects on vision and eye health in this population.

Age: 50Years - 90YearsAll GendersPhase 4
31 locations